Phase_1_TVS_3_Method_manuscript_Supplement_final_110421.docx (30.04 kB)
Download file

fon-2021-1437_suppl_data

Download (30.04 kB)
dataset
posted on 18.01.2022, 14:30 authored by Charles Peterfy, Yan ChenYan Chen, Peter Countryman, Bartosz Chmielowski, Stephen Patrick Anthony, John H Healey, Zev A. Wainberg, Allen Lee Cohn, Geoffrey I. Shapiro, Vicki L. Keedy, Arun Singh, Igor Puzanov, Andrew J. Wagner, Meng Qian, Mike Sterba, Sandra Tong-Starksen, Henry H. Hsu, William D. Tap

Table 1. Erosion Score Locations

Table 2. Cartilage Score Locations

Table 3. Bone Marrow Edema/Infiltration (BME) Score Locations

Table 4. Knee Locations and Scores

CSF1 Receptor Inhibition of Tenosynovial Giant Cell Tumor Using Novel Disease-Specific MRI Measures of Tumor Burden

Abstract

Background: Monitoring treatment of tenosynovial giant cell tumor (TGCT) is complicated by irregular shape and asymmetrical growth of the tumor. We compared responses to pexidartinib by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 with those to Tumor Volume Score (TVS) and modified-RECIST (m-RECIST). Methods: MRIs acquired every 2 cycles were assessed centrally using RECIST 1.1, m-RECIST, and TVS and tissue damage score (TDS). Results: Thirty-one evaluable TGCT patients were treated with pexidartinib. From baseline to last visit, 94% of patients (29/31) showed a decrease in tumor size (median change: −60% [RECIST], −66% [m-RECIST], −79% [TVS]). All methods showed 100% disease control rate. For TDS, improvements were seen in patients bone loss (36%), bone marrow edema (58%), knee effusion (46%). Conclusions: TVS and m-RECIST offer potentially superior alternatives to conventional RECIST for monitoring disease progression and treatment response in TGCT. TDS adds important information about joint damage associated with TGCT.

Funding

Merck

History